Bain and Cinven bid to acquire German drugmaker fails

27 June 2017
mergers-acquisitions-big

Shares of German generic and OTC drugmaker Stada Arzneimittel were down 8.1% at 58.15 euros in after-hours trading on the Frankfurt exchange yesterday, after it became clear that the proposed 5.3 billion euros ($5.9 billion), or 66 euros per share, acquisition of the company had failed to gain sufficient shareholder backing to proceed.

Nidda Healthcare Holding, the acquiring company of Bain Capital and Cinven, announced on Monday that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on June 22, 2017, only 65.52% of the Stada  shares outstanding have been tendered under the voluntary public takeover offer. Consequently, the minimum acceptance threshold, which the bidder reduced from the original 75% to 67.5% on June 7, 2017, has not been reached.

Bain and Cinven fought off bids from another private consortium comprised of Advent International and Permira. However, following the failed deal, it is seen as unlikely that Advent or Permira would bid again because their offer was below the one that had just collapsed. Also, Shanghai Pharmaceutical in May confirmed its interest in a takeover of Stada, but cautioned at the time that it had not submitted an official offer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics